JP6727129B2 - 環状プロサポシンペプチドおよびその使用 - Google Patents

環状プロサポシンペプチドおよびその使用 Download PDF

Info

Publication number
JP6727129B2
JP6727129B2 JP2016559300A JP2016559300A JP6727129B2 JP 6727129 B2 JP6727129 B2 JP 6727129B2 JP 2016559300 A JP2016559300 A JP 2016559300A JP 2016559300 A JP2016559300 A JP 2016559300A JP 6727129 B2 JP6727129 B2 JP 6727129B2
Authority
JP
Japan
Prior art keywords
peptide
cyclic
seq
cancer
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016559300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512799A5 (enExample
JP2017512799A (ja
Inventor
ワトニック，ランドルフ，エス．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of JP2017512799A publication Critical patent/JP2017512799A/ja
Publication of JP2017512799A5 publication Critical patent/JP2017512799A5/ja
Application granted granted Critical
Publication of JP6727129B2 publication Critical patent/JP6727129B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016559300A 2014-03-26 2015-03-26 環状プロサポシンペプチドおよびその使用 Active JP6727129B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461970853P 2014-03-26 2014-03-26
US61/970,853 2014-03-26
PCT/US2015/022745 WO2015148801A1 (en) 2014-03-26 2015-03-26 Cyclic prosaposin peptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020029398A Division JP7284726B2 (ja) 2014-03-26 2020-02-25 環状プロサポシンペプチドおよびその使用

Publications (3)

Publication Number Publication Date
JP2017512799A JP2017512799A (ja) 2017-05-25
JP2017512799A5 JP2017512799A5 (enExample) 2018-05-24
JP6727129B2 true JP6727129B2 (ja) 2020-07-22

Family

ID=54196396

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2016559300A Active JP6727129B2 (ja) 2014-03-26 2015-03-26 環状プロサポシンペプチドおよびその使用
JP2020029398A Active JP7284726B2 (ja) 2014-03-26 2020-02-25 環状プロサポシンペプチドおよびその使用
JP2023010162A Pending JP2023053978A (ja) 2014-03-26 2023-01-26 環状プロサポシンペプチドおよびその使用
JP2024170459A Pending JP2025010144A (ja) 2014-03-26 2024-09-30 環状プロサポシンペプチドおよびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020029398A Active JP7284726B2 (ja) 2014-03-26 2020-02-25 環状プロサポシンペプチドおよびその使用
JP2023010162A Pending JP2023053978A (ja) 2014-03-26 2023-01-26 環状プロサポシンペプチドおよびその使用
JP2024170459A Pending JP2025010144A (ja) 2014-03-26 2024-09-30 環状プロサポシンペプチドおよびその使用

Country Status (6)

Country Link
US (4) US10646541B2 (enExample)
EP (2) EP3122369B1 (enExample)
JP (4) JP6727129B2 (enExample)
CN (2) CN106659764B (enExample)
AU (4) AU2015235978B2 (enExample)
WO (1) WO2015148801A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020117504A (ja) * 2014-03-26 2020-08-06 ザ チルドレンズ メディカル センター コーポレーション 環状プロサポシンペプチドおよびその使用
US12117448B2 (en) 2007-06-22 2024-10-15 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
GB8518144D0 (en) 1985-07-18 1985-08-21 Univ Belfast Solid phase peptide synthesis
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US4794150A (en) 1987-03-11 1988-12-27 Samuel Steel Synthesis of peptide analogs
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
US5180816A (en) 1988-08-24 1993-01-19 Centocor One vial method for labeling protein/linker conjugates with technetium-99M
US5221754A (en) 1989-06-09 1993-06-22 Research Corporation Technologies, Inc. Reagents for rapid peptide synthesis
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
ES2149880T3 (es) 1993-06-29 2000-11-16 Ferring Bv Sintesis de peptidos ciclicos.
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5552471A (en) 1994-08-17 1996-09-03 The Perkin-Elmer Corporation Solid support reagents for the synthesis of 3'-Nitrogen containing polynucleotides
US6001966A (en) 1995-10-19 1999-12-14 Proligo Llc Method for solution phase synthesis of oligonucleotides and peptides
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US7176282B1 (en) 1996-09-09 2007-02-13 Zealand Pharma A/S Solid-phase peptide synthesis and agent for use in such synthesis
AU9774698A (en) 1997-09-09 1999-03-29 Regents Of The University Of California, The Inhibition of apoptotis using prosaposin receptor agonists
US6423685B1 (en) 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US7094943B2 (en) 1998-04-27 2006-08-22 Hubert Köster Solution phase biopolymer synthesis
US6638911B1 (en) * 1998-05-05 2003-10-28 Adherex Technologies Inc. Compounds and methods for modulating desmosomal cadherin-mediated functions
US6500431B1 (en) 1998-07-13 2002-12-31 University Of Southern California Inhibitors of angiogenesis and tumor growth
AUPP616498A0 (en) 1998-09-25 1998-10-15 University Of Queensland, The Synthesis of cyclic peptides
US6706252B1 (en) 1998-10-30 2004-03-16 Rx/Ibr Corporation Method of treating disease with radioisotopes conjugated to bioactive substances
US20020177551A1 (en) 2000-05-31 2002-11-28 Terman David S. Compositions and methods for treatment of neoplastic disease
US20020168639A1 (en) 2000-09-22 2002-11-14 Muraca Patrick J. Profile array substrates
CA2422707A1 (en) 2000-10-05 2002-04-11 Ares Trading S.A. Regioselective liquid phase pegylation
US7183118B2 (en) 2002-06-03 2007-02-27 The Institute For Systems Biology Methods for quantitative proteome analysis of glycoproteins
US20040219609A1 (en) 2002-07-12 2004-11-04 Day Anthony G. Methods for modulating proteins not previously known as proteases
US7166691B2 (en) 2002-12-20 2007-01-23 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Saposin C and receptors as targets for treatment of benign and malignant disorders
DK1605965T3 (da) 2003-03-26 2013-04-15 Evotec Internat Gmbh Anvendelse af saposin-beslægtede proteiner til forebyggelse og behandling af obesitet, diabetes og/eller metabolisk syndrom
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7834147B2 (en) 2003-04-28 2010-11-16 Childrens Hospital Medical Center Saposin C-DOPS: a novel anti-tumor agent
GB0318205D0 (en) 2003-08-02 2003-09-03 Albachem Ltd Synthetic method
WO2006119035A2 (en) 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. Vegf variants
US20070099251A1 (en) 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US20080090760A2 (en) 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
CN101573371A (zh) 2006-12-29 2009-11-04 弗·哈夫曼-拉罗切有限公司 环肽类化合物的合成方法
EP2190448B1 (en) * 2007-06-22 2016-04-20 Children's Medical Center Corporation Methods and uses thereof of a fragment of saposin a
US8027291B2 (en) 2007-09-27 2011-09-27 Wireless Technology Solutions Llc Method and apparatus for transmitting transport channels over a physical channel of a cellular communication system
CA2732108A1 (en) 2008-07-28 2010-02-04 Children's Medical Center Corporation Prominin-1 peptide fragments and uses thereof
EP3925670A1 (en) 2009-12-17 2021-12-22 Children's Medical Center, Corp. Saposin-a derived peptides and uses thereof
EP4306123A3 (en) * 2011-12-22 2024-04-17 Children's Medical Center Corporation Saposin-a derived peptides and uses thereof
CN118028464A (zh) 2013-03-14 2024-05-14 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
EP3122369B1 (en) * 2014-03-26 2022-08-31 Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12117448B2 (en) 2007-06-22 2024-10-15 Children's Medical Center Corporation Saposin-A derived peptides and uses thereof
JP2020117504A (ja) * 2014-03-26 2020-08-06 ザ チルドレンズ メディカル センター コーポレーション 環状プロサポシンペプチドおよびその使用
JP7284726B2 (ja) 2014-03-26 2023-05-31 ザ チルドレンズ メディカル センター コーポレーション 環状プロサポシンペプチドおよびその使用

Also Published As

Publication number Publication date
AU2021203082A1 (en) 2021-06-10
AU2015235978A1 (en) 2016-10-20
EP3122369B1 (en) 2022-08-31
US20240139279A1 (en) 2024-05-02
JP2020117504A (ja) 2020-08-06
EP3122369A4 (en) 2017-09-27
JP2025010144A (ja) 2025-01-20
US10646541B2 (en) 2020-05-12
EP3122369A1 (en) 2017-02-01
JP2017512799A (ja) 2017-05-25
JP7284726B2 (ja) 2023-05-31
JP2023053978A (ja) 2023-04-13
CN106659764B (zh) 2021-11-02
CA2943802A1 (en) 2015-10-01
AU2023204392A1 (en) 2023-08-03
CN113908253A (zh) 2022-01-11
US20220152146A1 (en) 2022-05-19
AU2019204952A1 (en) 2019-07-25
US20200246419A1 (en) 2020-08-06
WO2015148801A1 (en) 2015-10-01
US20170173109A1 (en) 2017-06-22
CN106659764A (zh) 2017-05-10
US11191805B2 (en) 2021-12-07
US11654178B2 (en) 2023-05-23
EP4154901A1 (en) 2023-03-29
AU2015235978B2 (en) 2019-08-08

Similar Documents

Publication Publication Date Title
US20240139279A1 (en) Cyclic prosaposin peptides and uses thereof
CN111787955B (zh) 特异于EphA2的双环肽配体
MX2011004019A (es) Conjugados de etoposido y doxorubicina para entrega de farmacos.
KR20190090872A (ko) 폴리에틸렌글리콜이 수식된 인테그린 차단제 hm-3 및 그 응용
JP7100639B2 (ja) Ｃｘｃｒ４アンタゴニストおよび使用方法
JP2024517518A (ja) マクロファージを標的とするペプチド、ならびにそのコンジュゲート、組成物、および使用
JP2023544223A (ja) 標的化ｐｅｔ／ｓｐｅｃｔ撮像のための放射性標識リガンド及びそれらの使用方法
CN116134138A (zh) 靶向细胞内诱瘤蛋白的抗体、或其单链可变片段与癌细胞穿透肽的融合蛋白、及其用途
HK40090948A (en) Cyclic prosaposin peptides and uses thereof
CA2943802C (en) Cyclic prosaposin peptides and uses thereof
KR102017973B1 (ko) 항-b형 간염 바이러스 x 단백질 폴리펩티드 약제
HK1233930B (en) Cyclic prosaposin peptides and uses thereof
HK1233930A1 (en) Cyclic prosaposin peptides and uses thereof
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
EP2670416B1 (en) A novel high affinity bivalent helically constrained peptide against cancer
KR20130060846A (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
WO2024252336A1 (en) Peptide compositions targeting glypican-3 and uses thereof
KR20250028290A (ko) 선택적 il-23 수용체 길항제로서의 새로운 펩티드

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180404

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191023

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200225

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20200413

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200630

R150 Certificate of patent or registration of utility model

Ref document number: 6727129

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250